Podcast Index
Browse podcasts by category, open recent episodes, and download audio to listen offline.
BioCentury This Week
BioCentury
Raising Hustle
Mariel Fry
Elettricista felice
Alessandro Bari
Espacio Diseño
Óyete Esto
Brushwood Media Network
Brushwood Media Network
ISF Podcast
Information Security Forum Podcast
The Call from ausbiz
ausbiz
Alternative Allocations with Tony Davidow
Franklin Templeton
Inside Out: Zichtbaar van binnenuit
Aurélie Veltema
Mobile Home Park Mastery
Frank Rolfe
阿司每日读书分享
阿司为您读书
Optimizing Your Google Business Profile for Maximum Visibility
GMB Crush
Remarkable Results Radio Podcast
Carm Capriotto, AAP
CFO Podcast
Peter De Roeck
AI Fire Daily
AIFire.co
Mining Stock Daily
Trevor Hall
Abraham Hicks
Abraham Hicks
Vancouver Rundown
Bruce Claggett
The Analytics Power Hour
Michael Helbling, Moe Kiss, Tim Wilson, Val Kroll, and Julie Hoyer
Tina Huang
Tina Huang
Alex Becker Channel
Alex Becker Channel
Morning Retail
BFM Business
L'éco and You
RTL
Roofing Success
Jim Ahlin
Spartan Leadership with Josh Kosnick
Josh Kosnick
Public Relations Stories and Strategies
Stories and Strategies https://storiesandstrategies.ca/
MENTOR360
Luis Ramos
All Ears English Podcast
Lindsay McMahon and Michelle Kaplan
The Bitcoin Standard Podcast
Dr. Saifedean Ammous
The Art of Growth
Joel Hubbard and Jim Zartman
The Insurance Coffee House with Nick Hoadley
Insurance Search
3 Takeaways™
Lynn Thoman
Driven by Data: The Podcast
Orbition Group
Clinician to CEO : Export Your Medical Device With Confidence By Overcoming Go To Market Roadblocks For Medtech Growth
Hakeem Adebiyi
Gewoon Doen: Ondernemersradio voor en door ondernemers met FastForwardAmy
Amy Vandeputte
Connected FM
IFMA
Sold Out Offers
Ceels Lockley | Offer Strategy Expert
Business
BioCentury
Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury’s analysts discuss how...
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts re...
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeo...
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $...
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Round...
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdi...
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data...
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to t...
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin disc...
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer I...
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the lates...
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCe...
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make ...
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-i...
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASD...
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, ...
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentur...
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a f...
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury’s Paul Bonanos assesses last week’s deals by Merck, which is lay...
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built...
Fill in the form below. Make sure to select both Country and Genres.
Send us a message below. We will get back to you within 24 hours.